Details of the Drug Combination

General Information of Drug Combination (ID: DC4HPMP)

Drug Combination Name

TAK-733 Ixazomib

Indication

Disease Entry	Status	REF
Glioblastoma	Investigative	[1]

Component Drugs

TAK-733 DMC4RNA

Ixazomib DM5ZVLB

Small molecular drug

N.A.

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: JHH-136

Zero Interaction Potency (ZIP) Score: 24.687

Bliss Independence Score: 25.146

Loewe Additivity Score: 3.11

LHighest Single Agent (HSA) Score: 5.925

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of TAK-733

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

TAK-733 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
MAPK/ERK kinase kinase (MAP3K)	TTROQ37	NOUNIPROTAC	Modulator	[4]
------------------------------------------------------------------------------------

Indication(s) of Ixazomib

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[3]

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	ClinicalTrials.gov (NCT00948467) Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies. U.S. National Institutes of Health.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015
4	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.